Optimal control of acute cisplatin-induced emesis

被引:24
作者
Verweij, J
deWit, R
deMulder, PHM
机构
[1] UNIV HOSP,ROTTERDAM,NETHERLANDS
[2] UNIV NIJMEGEN HOSP,DEPT INTERNAL MED,DIV MED ONCOL,NL-6500 HB NIJMEGEN,NETHERLANDS
关键词
chemotherapy-related emesis; 5-HT3; antagonists; antiemetics; cisplatin-induced emesis;
D O I
10.1159/000227642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A survey by Coates and co-workers in 1983 revealed that patients ranked nausea and vomiting as the most distressing side effects of chemotherapy. In the last decade the use of high-dose metoclopramide and, especially, the introduction of the 5-HT3 receptor antagonists, have been major leaps forward in the control of chemotherapy-induced emesis. Nevertheless, since patients still consider nausea and vomiting to be the most distressing side effect of their chemotherapy there is clearly a need for further improvements. Acute emesis, which is the topic of this review, can now be controlled in the majority of patients during their first course of chemotherapy. Future focus should be on better control of emesis during subsequent courses of chemotherapy as well as on better control of delayed emesis.
引用
收藏
页码:56 / 64
页数:9
相关论文
共 86 条
[21]  
DEBOER M, 1993, EUR J CANC A S6, V29, P264
[22]   Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting - A Multicenter, Randomized, Double-Blind, Crossover Study [J].
Demulder, PHM ;
Seynaeve, C ;
Vermorken, JB ;
Vanliessum, PA ;
Molsjevdevic, S ;
Allman, EL ;
Beranek, P ;
Verweij, J .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (11) :834-840
[23]  
DEWET M, 1993, CANCER, V71, P4043, DOI 10.1002/1097-0142(19930615)71:12<4043::AID-CNCR2820711239>3.0.CO
[24]  
2-A
[25]   Analysis of cumulative probabilities shows that the efficacy of 5HT(3) antagonist prophylaxis is not maintained [J].
deWit, R ;
Schmitz, PIM ;
Verweij, J ;
deBoerDennert, M ;
deMulder, PHM ;
Planting, AST ;
vanderBurg, MEL ;
Stoter, G .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :644-651
[26]   ONDANSETRON - A NEW ANTIEMETIC FOR PATIENTS RECEIVING CISPLATIN CHEMOTHERAPY [J].
EINHORN, LH ;
NAGY, C ;
WERNER, K ;
FINN, AL .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) :731-735
[27]   ONDANSETRON VERSUS ONDANSETRON, DEXAMETHASONE, AND CHLORPROMAZINE IN THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MULTIPLE-DAY CISPLATIN CHEMOTHERAPY [J].
FOX, SM ;
EINHORN, LH ;
COX, E ;
POWELL, N ;
ABDY, A .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2391-2395
[28]   RANDOMIZED CROSSOVER ANTIEMETIC STUDY IN CISPLATIN-TREATED PATIENTS - COMPARISON BETWEEN HIGH-DOSE IV METOCLORPRAMIDE AND HIGH-DOSE IV DEXAMETHASONE [J].
FRUSTACI, S ;
GRATTONI, E ;
TUMOLO, S ;
CRIVELLARI, D ;
FIGOLI, F ;
GALLIGIONI, E ;
VERONESI, A ;
TIRELLI, U ;
GRIGOLETTO, E .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 17 (01) :75-79
[29]  
GORDON CJ, 1989, CANCER, V63, P578, DOI 10.1002/1097-0142(19890201)63:3<578::AID-CNCR2820630330>3.0.CO
[30]  
2-Z